ClearWaste is a price comparison website for waste removal and a provider of enforcement services to councils across the UK. The company argues that the cost to local authorities and taxpayers for cleaning up fly-tipping in England in 2016/17 was £57.7 million and is now thought to exceed £100 million. ClearWaste is on a mission to combat it through its app and web platform utilising reporting and prevention methodologies. The company links consumers with govt-registered waste removers backed by a £1k no-fly-tipping guarantee. ClearWaste argues that the UK waste industry is worth over £6.8 billion and supports more than 103,000 jobs. It aims to be a contender in this segment. ClearWaste has featured in press entities such as BBC, ITV, Channel 5, Sky, Times, and The Guardian. It was also a finalist at the National Recycling Awards 2020. ClearWaste will use the investment to develop its sales and marketing functions and further raise brand awareness.
days to go:
Expired
investment:
£199,599
Vyomm is a property platform based in London for sellers, buyers and agents of Prime and Super Prime properties. Vyomm aims to become a preferred destination for Luxury, Exclusive, and Off Market Properties in London. Their engaging platform has gained substantial traction with several hundred Prime Central London properties. They have featured in Tatler, PrimeResi, Mirror and 12 other publications. With the investment, Vyomm plans to onboard top estate agents in London, expand into Asia, Europe and the USA, marketing and developmental operations.
days to go:
Expired
investment:
£178,280
Plantwork Systems (PWS) is an eco-conscious, technology company providing sustainable and environmentally friendly solutions to the wastewater treatment industry. It is the developer, owner, and provider of a range of proprietary technologies such as TN-REM, NUTREM®, and the deHoxar Spiral Separator. These products aid in nutrient removal, improved filtration, sludge thickening. This leads to wastewater treatment plants recycling more water, reducing their energy requirements, and minimising water scarcity. The company has generated combined revenues of £1.44 million since July 2017. PWS is seeking funding of up to £1 million, at a pre-money valuation of £6 million. It will use the investment to accelerate its growth and bring more innovative products to the market.
days to go:
Expired
investment:
£244,865
My Tree has launched a Memorial Park in the UK that enables people to plant a tree with the ashes of their loved one. It is the sole exclusive UK memorial park which offers ashes burial with the planting of a tree. The company is in discussion with DoubleTree Hilton and First Funerals. My Tree has launched its first park five miles outside of Reading and 38 miles from London. The company will use the funds to promote the site, do pre-planting to maximize usage of space and support plans to open more sites by the end of 2020.
days to go:
Expired
investment:
£160,380
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen £14 million worth of investment on its portal to date. Brickowner will use the investment towards technology up-gradation, hire strategic personnel to expand marketing, and increase its marketing spend.
days to go:
Expired
investment:
£132,528
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company asserts that it undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen over £15 million worth of investments on its portal till date. Brickowner will use the investment towards technology up-gradation, develop its B2B capacity, and increase marketing initiatives to support company growth
days to go:
Expired
investment:
£290,362
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
